Pyrazolopyrimidines: A promising frontier in cancer treatment‐ Reviewing their potential as inhibitors of serine/threonine kinases

Pyrazolopyrimidine derivatives have emerged as potent inhibitors targeting a broad spectrum of kinases, particularly serine/threonine kinases. This review provides a comprehensive overview of the synthesis, structural modifications, and pharmacological relevance of pyrazolopyrimidine compounds in the realm of kinase inhibition. Specifically, the focus is placed on their inhibitory action against serine/threonine kinases, key players in cell signaling and potential therapeutic targets in various diseases, especially cancer. The structure‐activity relationship (SAR) of these derivatives, highlights the importance of specific substituents in enhancing inhibitory activity, Pyrazolopyrimidine derivatives have shown promising inhibitory activity against certain serine/threonine kinases. The exact mechanism by which these compounds inhibit kinase activity usually involves binding to the ATP‐binding site of the kinase, thereby preventing ATP from binding and the kinase from undergoing its usual phosphorylation activity, while pyrazolopyrimidine derivatives show promise as serine/threonine kinase inhibitors, challenges remain, including issues related to drug resistance, off‐target effects, and potential toxicity. Future research is geared towards designing more selective derivatives with improved pharmacokinetic properties and reduced side effects.